China IVD Reagent Market: Biochemical, Immune & Molecular Products to Drive Growth to 2017 Say New Research Reports RnRMarketResearch.com now offers "Research on China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2013-2017" and "Research Report on Global and China In-vitro Diagnostic Reagent Industry, 2013-2017" reports in its store.
DALLAS, Aug. 7, 2013 /PRNewswire-iReach/ -- In 2012, the scale of China's IVD market reached CNY 19 billion, of which, the scale of IVD reagent market was CNY 13.8 billion. These research reports predict that the growth rate of the market scale of China's in-vitro diagnostics will be markedly higher than the global average level and the CAGR will maintain over 15% from 2013 to 2017. By 2017, the market scale will reach CNY 30 billion, among which immune and biochemical products will continually occupy most of the market share, while the proportion of molecular products will relatively increase. During the upgrading of products in the future and the process of domestic substitution, the industry concentration rate will grow.
The report "Research on China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2013-2017" (http://www.rnrmarketresearch.com/research-on-china-ivd-reagent-in-vitro-diagnostic-reagent-industry-2013-2017-market-report.html) mainly conducts in-depth analysis on the external environment, market operation, import &export, as well as other aspects of China's IVD reagent industry, and also summaries the latest development state in 2012 of key domestic enterprises, and finally forecasts the future industrial development. The information can provide investors with decision-making reference. Companies discussed in this report include: Shanghai Kehua Bio-engineering Co., Ltd., DAAN Gene Co., Ltd., Shanghai Fosun Pharmaceutical (Group) CO., Ltd., BioSino Bio-technology and Science Inc., Beijing Leadman Biochemistry Co., Ltd. and Beijing Wantai Biological Pharmacy Enterprise Co., Ltd..
The research "Research Report on Global and China In-vitro Diagnostic Reagent Industry, 2013-2017" (http://www.rnrmarketresearch.com/research-report-on-global-and-china-in-vitro-diagnostic-reagent-industry-2013-2017-market-report.html) says in Chinese market, there are mainly three categories of in-vitro diagnostic reagents, biochemical diagnostic reagents, immune diagnostic reagents and molecular diagnostic reagents, accounting for about 65% of in-vitro diagnostic reagent market in total in 2012. China's population accounts for more than 20% of the world's population, while the market share of in-vitro diagnostics is less than 5% of the world's; in 2012, the annual consumption per capita of China's in-vitro diagnostic products was less than USD 2, while that of developed countries reached USD 25 to USD 30. Therefore, there is a wide growth space for China's in-vitro diagnostics. Global companies discussed in this report include: F. Hoffmann-La Roche, Ltd., Siemens AG and Abbott Laboratories whereas Top 5 enterprises of China's IVD reagent industry covered are: Shanghai Kehua Bio-engineering Co., Ltd., Shanghai Fosun Pharmaceutical Co., Ltd., DAAN Gene Co., Ltd. of Sun Yat-sen University, Beijing Leadman Biochemistry Co., Ltd. and BioSino Bio-technology and Science Inc..
In recent years, China's IVD reagent industry has entered the development phase from the introduction stage, and the market demand increased rapidly; domestic enterprises grasped opportunities by virtue of the advantages of high performance cost ratio and closer to the local market, and seized the market share constantly; thus, the market pattern which was dominated by the imported products is breaking down gradually. With the strengthening of R&D investment and the improvement of products quality, a number of local enterprises with relatively strong strength have appeared in China's IVD reagent industry, which concentrated in biochemical, immune and molecular diagnoses fields, some products have owned the ability to compete with the international giants.
The state policy encourages the competitive enterprises to strengthen their strength. In 2013, a series of policies which target to improve industry standard and threshold will enter the substantive operation stage, which will accelerate the elimination of small enterprises and improve the industry concentration ratio, industrial consolidation is the development trend, and the enterprises with capital, technology and scale advantages will win gradually.
Purchase a copy of one or both reports by visiting the following links:
Research on China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2013-2017 @ http://www.rnrmarketresearch.com/contacts/purchase?rname=110252.
Research Report on Global and China In-vitro Diagnostic Reagent Industry, 2013-2017 @ http://www.rnrmarketresearch.com/contacts/purchase?rname=109040.
You may also be interested in a similar report titled:
In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017.
Explore more reports on the In Vitro Diagnostic market and its related areas @ http://www.rnrmarketresearch.com/reports/life-sciences/diagnostics/in-vitro-diagnostics-ivd.
RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Explore more reports @ http://marketreportsstore.com/.
Media Contact: Priyank Tiwari, RnR Market Research, +1 888 391 5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research